Compare ASIX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASIX | RCKT |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.1M | 239.3M |
| IPO Year | 2016 | 2014 |
| Metric | ASIX | RCKT |
|---|---|---|
| Price | $15.68 | $2.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $20.00 | $8.58 |
| AVG Volume (30 Days) | 212.4K | ★ 2.2M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | 11.11 | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | ★ $1,684,625,000.00 | N/A |
| Revenue This Year | $9.86 | N/A |
| Revenue Next Year | $5.06 | $915.60 |
| P/E Ratio | ★ N/A | $3.50 |
| Revenue Growth | ★ 45.49 | N/A |
| 52 Week Low | $14.10 | $2.17 |
| 52 Week High | $26.73 | $5.45 |
| Indicator | ASIX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 37.77 |
| Support Level | $15.46 | N/A |
| Resistance Level | $16.93 | $3.70 |
| Average True Range (ATR) | 0.44 | 0.18 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 30.73 | 18.70 |
AdvanSix Inc is a diversified chemistry company playing a critical role in international supply chains, innovating and delivering essential products for customers across a wide variety of end markets and applications that touch people's lives, including building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, and electronics. The company's key products include Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates. The majority of sales are from Plant Nutrients products. The company operates in the United States and internationally, with the majority of revenue coming from the United States.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.